INTS · Intensity Therapeutics, Inc.

Summary

Intensity Therapeutics, Inc. received a letter from Nasdaq on March 5, 2026, confirming it has regained compliance with Nasdaq Listing Rule 5550(a)(2) Minimum Bid Price Requirement after maintaining a $1.00 per share closing bid price for 10 consecutive business days from February 19 to March 4, 2026. The matter is now closed, following prior noncompliance notices in June 2025 and December 2025.

Key takeaways

• Received Nasdaq compliance letter on March 5, 2026
• Regained compliance with Minimum Bid Price Requirement under Rule 5550(a)(2)
• Maintained $1.00 closing bid price for 10 business days: February 19–March 4, 2026
• Initial noncompliance notice: June 6, 2025 (180 days to December 3, 2025)
• Second notice: December 4, 2025 (additional 180 days to June 1, 2026)
• Issued press release on March 6, 2026 (Exhibit 99.1)